tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Conduit Pharmaceuticals Enters Joint Development Agreement

Story Highlights
  • Conduit Pharmaceuticals entered a joint development agreement with Manoira to explore AZD1656 and AZD5658 in animal health.
  • The collaboration aims to generate cross-species insights and tap into the $15 billion animal health market.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Conduit Pharmaceuticals Enters Joint Development Agreement

Elevate Your Investing Strategy:

Conduit Pharmaceuticals ( (CDT) ) has provided an announcement.

On June 3, 2025, Conduit Pharmaceuticals entered a joint development agreement with Manoira Corporation to explore the applicability of its glucokinase activators, AZD1656 and AZD5658, in animal health. This collaboration aims to generate valuable cross-species insights and accelerate Conduit’s human clinical programs while maintaining full ownership of intellectual property. The partnership allows Conduit to tap into the $15 billion animal health market, potentially creating new revenue streams and enhancing shareholder value.

More about Conduit Pharmaceuticals

Conduit Pharmaceuticals is a dynamic, multi-asset clinical stage life science company that focuses on acquiring and funding the development of Phase 2-ready assets. The company employs an integrated platform-driven approach powered by artificial intelligence and cybernetics, aiming for exits through third-party license deals after successful clinical trials. Conduit is led by experienced pharmaceutical executives, including Dr. Andrew Regan and Dr. Freda Lewis-Hall.

Average Trading Volume: 328,252

Technical Sentiment Signal: Sell

Current Market Cap: $2.03M

Learn more about CDT stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1